Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24+ gastrointestinal cancer patients

Journal of Cancer Research and Clinical Oncology

Volumn 128, Issue 9, 2002, Pages 507-515

  Hao, Xishan ^a   Shao, Ying ^a   Ren, Xiubao ^a   Liu, Hong ^a   Xu, Qi ^a   Li, Hui ^a   Zhang, Peng ^a   An, Xiumei ^a   Ren, Baozhu ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

CEA; CTL; Dendritic cell; MAGE; Peptide vaccine

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; HLA A ANTIGEN; INTERLEUKIN 2; MELANOMA ANTIGEN; PROTEIN SUBUNIT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 4;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN CELL; MALE; PILOT STUDY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GASTROINTESTINAL NEOPLASMS; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036381606     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-002-0358-x     Document Type: Article

References (42)

1. Abbes, Abul K, et al (1997) Cellular and molecular immunology, 3rd edn. Saunders, Philadelphia, pp 451-510
2. Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM (2000) The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother 49:517-529
3. Becker Y (1993) Dendritic cell activity against primary tumors: an overview. In vivo 7:187-191
4. Bernhard H, Disis ML, Heimfeld S, Hand S, Gralow JR, Cheever MA (1995) Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res 55:1099-1104
5. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr (1999) Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide. Cancer Immunol Immunother 48:189-194
6. Fujie T, Tanaka F, Tahara K, Li J, Tanaka S, Mori M, Ueo H, Takesako K, Akiyoshi T (1996) Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183:283-287
7. Grabbe S, Beissert S, Schwarz T, Granstein RD (1995) Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 16:117-121
8. Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1996) Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 56:2479-2483
9. Inaba K, Inaba M, Naito M, Steinman RM (1993) Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J Exp Med 178:479-488
10. Inoue H, Mori M, Honda M, Li J, Shibuta K, Mimori K, Ueo H, Akiyoshi T (1995) The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 109:1522-1525
11. Kanaoka S, Yamasaki S, Okino T, Inoue N, Shimada Y, Kaneko M, Otaka A, Fujii N, Imamura M (1999) Induction of human leukocyto antigen (HLA)-A2-restricted and MAGE-3 gene derived peptide specific cytolytic T lymphocytes using cultured dendritic cells from an HLA-A2 esophageal cancer patients. J Surg Oncol 71:16-21
12. Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J (1992a) Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccina virus vaccine. J Natl Cancer Inst 84:1084-1091
13. Kantor J, Irvine K, Abrams S, Snoy P, Olsen R, Greiner J, Kaufman H, Eggensperger D, Schlom J (1992b) Immunogenicity and safety of a recombinant vaccina virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 52:6917-6925
14. Kim DK, Lee TV, Castilleja A, Anderson BW, Peoples GE, Kudelka AP, Murray JL, Sittisomwong T, Wharton JT, Kim JW, Ioannides CG (1999) Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. Anticancer Res 19:2907-2916
15. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL (1993) ECcient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A 90:4942-4946
16. Li J, Yang Y, Fujie T, Tanaka F, Mimori K, Haraguchi M, Ueo H, Mori M, Akiyoshi T (1997) Expression of the MAGE gene family in human gastric carcinoma. Anticancer Res 17:3559-3563
17. Linette GP, Shankara S, Longerich S, Yang S, Doll R, Nicolette C, Preffer FI, Roberts BL, Haluska FG (2000) In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma. J Immunol 164:3402-3412
18. Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V, Lindemann A (2000) Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Int J Cancer 86:385-392
19. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219-230
20. Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu MZ, Schlom J (1996) Results of a phase I trial of a a recombinant vaccina virus that expresses carcinoembryonic antigen gene in patients with advanced colorectal cancer. Ann Surg Oncol 3:495-500
21. McAneny D, Ryan CA, Beazley RM, Kaufman HL (1999) Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 17:332-337
22. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK (1999) A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 5:1331-1338
23. Nair SK, Snyder D, Rouse BT, Gilboa E (1997) Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 70:706-715
24. Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, Murai M (2001) Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 7:23-31
25. Ofuji S, Ikeda M, Tsujitani S, Ikeguchi M, Kaibara N, Yuasa I, Mitsuya K, Katoh M, Ito H (1998) Expression of MAGE-1, MAGE-2 and MAGE-3 genes in human gastric carcinomas; lack of evidence for cytotoxic effects in cases with simultaneous expression of MAGE-3 and HLA-A2. Anticancer Res 18:3639-3644
26. Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA, Marincola FM (2000) Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 23:487-498
27. Parkin DM, Welan SL, Ferlay J, Raymond L, Yong J (2001) Cancer incidence in five continents VIII. IACR Scientific, Singapore, pp 330-333
28. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83-93
29. Rosenberg S (2000) Principles and practice of the biologic therapy of cancer, 3rd edn. Lippincott, Philadelphia, pp 499
30. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M (2001) Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastriointestinal carcinoma. Clin Cancer Res 7:2277-2284
31. Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, Roder C, Haendle I, Leisgang W, Dunbar R, Cerundolo V, von Den Driesch P, Knop J, Brocker EB, Enk A, Kampgen E, Schuler G (2000) Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol 165:3492-3496
32. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296
33. Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T (1999) Identification of a MAGE-2-encoded human leukucyte antigen A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 5:2236-2241
34. Tarte K, Klein B (1999) Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. Leukemia 13:653-663
35. Thompson JA, Grunert F, Zimmermann W (1991) Carcinoembryonic antigen gene famliy: molecular biology and clinical prospectives. J Clin Lab Anal 5:344-366
36. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-1678
37. Timmerman JM, Levy R (1999) Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50:507-529
38. Toungouz M, Libin M, Bulte F, Faid L, Lehmann F, Duriau D, Laporte M, Gangji D, Bruyns C, Lambermont M, Goldman M, Velu T (2001) Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol 69:937-943
39. Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E (1999) A phase I trial of an HLA-A1 restricted MAGE-3 epitope pepetide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother 22:431-440
40. Zbar AP, Lemoine NR, Wadhwa M, Thomas H, Snary D, Kmiot WA (1998) Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target. Br J Cancer 77:683-693
41. Zhen Y (1998) Immunology of cancer. In: Hubei, Science and technology, pp 7-20
42. Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY (2000) Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 6:24-33